A systematic review of the evidence for pharmacist care of patients with dyslipidemia

Pharmacotherapy

Volumn 32, Issue 3, 2012, Pages 222-233

  Charrois, Theresa L ^a   Zolezzi, Monica ^b,c   Koshman, Sheri L ^c   Pearson, Glen ^c   Makowsky, Mark ^c   Durec, Tamara ^d   Tsuyuki, Ross T ^c  

^a CURTIN UNIVERSITY   (Australia)

^b ALBERTA HEALTH SERVICES   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Durec Information Services Inc   (Canada)

Author keywords

Disease management; Lipids; Pharmacist management; Systematic review

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; HUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACIST ATTITUDE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT CARE; PHARMACISTS; PROFESSIONAL ROLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864594604     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01022.x     Document Type: Review

References (38)

1. National Cholesterol Education Program. Detection, Evaluation and Treatment of high blood cholesterol in adults (adult treatment panel III). NIH Publication No. 02-5215 September 2002. Available from http://www.nhlbi.nih.gov/ guidelines/cholesterol/atp3full.pdf. Accessed January 30, 2012.
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
4. Davidson MH, Gandhi SK, Ohsfeldt RL, Fox KM. Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Am J Med 2009;122(1 suppl):S51-9.
5. Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: A retrospective cohort analysis. Clin Ther 2007;29:742-50.
6. Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: Systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother 2008;42:1195-207.
7. Shiu JR, Simpson SH, Johnson JA, Tsuyuki RT. Quantifying opportunities to affect diabetes management in the community. CPJ 2006;139:37-8.
8. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias of included studies. In: Cochrane handbook for systematic reviews of interventions v5.0.2. [updated September 2009]. Higgins JPT, Green S, eds. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org. Accessed September 1, 2010.
9. Deeks JJ, Higgins JPT, Altman DG. Section 9.4.5.2 meta-analysis of change scores. In: Cochrane handbook for systematic reviews of interventions v5.0.2. [updated September 2009]. Higgins JPT, Green S, eds. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org. Accessed September 1, 2010.
10. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43.
11. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000;20:1508-16.
12. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counselling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: A randomized, controlled trial. Pharmacotherapy 2000;20:410-6.
13. Nola KM, Gourley DR, Portner TS, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc (Wash) 2000;40:166-73.
14. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
15. Taylor CT, Byrd DC, Krueger K. Improving primary care in rural Alabama with a pharmacy initiative. Am J Health Syst Pharm 2003;60:1123-9.
16. Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Stewart K, Krum H. Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. J Clin Pharm Ther 2004;29:23-30.
17. Clifford RM, Davis WA, Batty KT, Davis TM. Fremantle Diabetes Study. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 2005;28:771-6.
18. Paulós CP, Nygren CE, Celedón C, Cárcamo CA. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Ann Pharmacother 2005;39:939-43.
19. Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: A randomized controlled trial. Am J Manag Care 2005;11:253-60.
20. Fornos JA, Andrés NF, Andrés JC, Guerra MM, Egea B. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci 2006;28:65-72.
21. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA 2006;296:2563-71.
22. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm 2006;63:2116-22.
23. Community Pharmacy Medicines Management Project Evaluation Team. The MEDMAN study: A randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract 2007;24:189-200.
24. Chiu CC, Wu SS, Lee PY, Huang YC, Tan TY, Chang KC. Control of modifiable risk factors in ischemic stroke outpatients by pharmacist intervention: An equal allocation stratified randomized study. J Clin Pharm Ther 2008;33:529-35.
25. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol 2009;67:547-57.
26. Doucette WR, Witry MJ, Farris KB, McDonough RP. Community pharmacist-provided extended diabetes care. Ann Pharmacother 2009;43:882-9.
27. Lee VW, Fan CS, Li AW, Chau AC. Clinical impact of a pharmacist-physician co-managed programme on hyperlipidaemia management in Hong Kong. J Clin Pharm Ther 2009;34:407-14.
28. Villa LA, Von Chrismar AM, Oyarzun C, Eujenin P, Fernandez ME, Quezada M. Pharmaceutical care program for dyslipidemic patients at three primary health care centers: Impacts and outcomes. Lat Am J Pharm 2009;28:415-20.
29. Eussen SRBM, van der Elst ME, Lungel OH, et al. A pharmaceutical care program to improve adherence to statin therapy: A randomized controlled trial. Ann Pharmacother 2010;44:1905-13.
30. Tahaineh L, Albsoul-Younes A, Al-Ashqar E, Habeb A. The role of clinical pharmacist on lipid control in dyslipidemic patients in north of Jordan. Int J Clin Pharm 2011;33:229-36.
31. Charrois TL, Tsuyuki RT. Comment: Sensitivity of patient outcomes to pharmacist interventions. Part III: Systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother 2009;43:793-4.
32. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org. Accessed September 1, 2010.
33. Peterson AM, Takiya L, Finley R. Meta-analysis of interventions to improve drug adherence in patients with hyperlipidemia. Pharmacotherapy 2003;23:80-7.
34. Schedlbauer A, Schroeder K, Fahey T. How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials. Fam Pract 2007;24:380-7.
35. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15.
36. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: A systematic review of randomized trials. Arch Intern Med 2008;168:687-94.
37. Charrois TL, Johnson JA, Blitz S, Tsuyuki RT. Relationship between number, timing, and type of pharmacist interventions and patient outcomes. Am J Health Syst Pharm 2005;62:1798-801.
38. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: A systematic review. Pharmacotherapy 2008;28:421-36.